PBRM1 and non-small cell lung carcinoma: ARID2 has also been identified as one of the most frequently altered genes in non-small cell lung cancer [20], gallbladder cancer [21], and metastatic breast cancer [22], and its deficiency can hamper DNA repair processes and enhance the sensitivity of lung cancer cells to DNA-damaging agents [23]. PBRM1 encodes polybromo 1, a specific subunit of the PBAF complex, and reportedly, in clinical practice, PBRM1 LOF variations favor the therapeutic effect of immune checkpoint inhibitors (ICIs) in renal cell carcinomas [24–26].